CN101035761B - 作为聚(adp-核糖)聚合酶(parp)抑制剂、治疗由坏死或细胞程序死亡导致的组织损伤或疾病的3,6-取代的5-芳基氨基-1h-吡啶-2-酮衍生物和相关化合物 - Google Patents

作为聚(adp-核糖)聚合酶(parp)抑制剂、治疗由坏死或细胞程序死亡导致的组织损伤或疾病的3,6-取代的5-芳基氨基-1h-吡啶-2-酮衍生物和相关化合物 Download PDF

Info

Publication number
CN101035761B
CN101035761B CN2005800338248A CN200580033824A CN101035761B CN 101035761 B CN101035761 B CN 101035761B CN 2005800338248 A CN2005800338248 A CN 2005800338248A CN 200580033824 A CN200580033824 A CN 200580033824A CN 101035761 B CN101035761 B CN 101035761B
Authority
CN
China
Prior art keywords
alkyl
ethyl
methyl
pyridin
ylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2005800338248A
Other languages
English (en)
Chinese (zh)
Other versions
CN101035761A (zh
Inventor
S·波伊克特
S·居斯雷根
A·霍德梅斯特尔
H·施罗伊德
U·施万
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Publication of CN101035761A publication Critical patent/CN101035761A/zh
Application granted granted Critical
Publication of CN101035761B publication Critical patent/CN101035761B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2005800338248A 2004-10-15 2005-10-05 作为聚(adp-核糖)聚合酶(parp)抑制剂、治疗由坏死或细胞程序死亡导致的组织损伤或疾病的3,6-取代的5-芳基氨基-1h-吡啶-2-酮衍生物和相关化合物 Expired - Fee Related CN101035761B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004050196.3 2004-10-15
DE102004050196A DE102004050196A1 (de) 2004-10-15 2004-10-15 Substituierte 2-Pyridon-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
PCT/EP2005/010697 WO2006042638A1 (de) 2004-10-15 2005-10-05 3,6-substituierte 5-arylamino-1h-pyidin-2-on derivative und verwandte verbindungen als poly(adp-ribose)polymerase (parp) inhibitoren zur behandlung von durch nekose oder apoptose verursachten gewebeschäden oder erkankungen

Publications (2)

Publication Number Publication Date
CN101035761A CN101035761A (zh) 2007-09-12
CN101035761B true CN101035761B (zh) 2010-06-02

Family

ID=35414525

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800338248A Expired - Fee Related CN101035761B (zh) 2004-10-15 2005-10-05 作为聚(adp-核糖)聚合酶(parp)抑制剂、治疗由坏死或细胞程序死亡导致的组织损伤或疾病的3,6-取代的5-芳基氨基-1h-吡啶-2-酮衍生物和相关化合物

Country Status (16)

Country Link
US (1) US7863280B2 (cg-RX-API-DMAC7.html)
EP (1) EP1802578B1 (cg-RX-API-DMAC7.html)
JP (1) JP4875623B2 (cg-RX-API-DMAC7.html)
KR (1) KR20070063005A (cg-RX-API-DMAC7.html)
CN (1) CN101035761B (cg-RX-API-DMAC7.html)
AT (1) ATE393146T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005297570C1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0516516A (cg-RX-API-DMAC7.html)
CA (1) CA2583565A1 (cg-RX-API-DMAC7.html)
DE (2) DE102004050196A1 (cg-RX-API-DMAC7.html)
DK (1) DK1802578T3 (cg-RX-API-DMAC7.html)
ES (1) ES2304721T3 (cg-RX-API-DMAC7.html)
IL (1) IL182093A (cg-RX-API-DMAC7.html)
MX (1) MX2007003360A (cg-RX-API-DMAC7.html)
PT (1) PT1802578E (cg-RX-API-DMAC7.html)
WO (1) WO2006042638A1 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1572514A4 (en) * 2002-10-16 2007-09-26 Transp Systems Inc DISTRIBUTION SYSTEM FOR ONE RAILWAY
US7961081B2 (en) * 2003-05-22 2011-06-14 John Tomlienovic Anti-theft system and method
SG164368A1 (en) 2005-07-18 2010-09-29 Bipar Sciences Inc Treatment of cancer
AU2007292306A1 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by PARP inhibitors and methods of treatment thereof
WO2008030883A2 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Treatment of cancer
US8124610B2 (en) 2007-07-13 2012-02-28 Icagen Inc. Sodium channel inhibitors
KR20100102609A (ko) 2007-11-12 2010-09-24 바이파 사이언스 인코포레이티드 Ｐａｒｐ 억제제를 단독으로 사용하거나 항종양제와 병용하여 유방암을 치료하는 방법
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
CA2798697A1 (en) 2010-05-10 2011-11-17 Radikal Therapeutics Inc. Lipoic acid and nitroxide derivatives and uses thereof
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
WO2017013237A1 (en) 2015-07-23 2017-01-26 Institut Curie Use of a combination of dbait molecule and parp inhibitors to treat cancer
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
AU2018260094A1 (en) 2017-04-28 2019-11-07 Akribes Biomedical Gmbh A PARP inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing
ES3008911T3 (en) 2017-07-11 2025-03-25 Vertex Pharma Carboxamides as modulators of sodium channels
AU2019235337A1 (en) 2018-03-13 2020-08-27 Centre National De La Recherche Scientifique A Dbait molecule against acquired resistance in the treatment of cancer
WO2020012357A1 (en) * 2018-07-10 2020-01-16 Integral Biosciences Pvt. Ltd. Heterocyclic compounds and methods of use
US12441703B2 (en) 2019-01-10 2025-10-14 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2020146612A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
US12351556B2 (en) 2019-10-04 2025-07-08 Inserm (Institut National De La Sante Et De La Recherche Medicale) Pyridin-2(1H)one derivatives, their preparation and their use for the treatment of pain
EP4065099A4 (en) 2019-11-25 2023-11-29 The Research Foundation for The State University of New York COMBINATION THERAPY USING FABP5 INHIBITORS WITH TAXANS FOR THE TREATMENT OF CANCER
US20230348401A1 (en) * 2020-01-15 2023-11-02 The Trustees Of Princeton University Inhibitors of Glucose-6-phosphate Dehydrogenase and Uses Thereof
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
AU2024312126A1 (en) 2023-06-21 2025-12-11 Tetragon Biosciences Ltd. Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0109628A1 (en) * 1982-11-18 1984-05-30 Sterling Drug Inc. 2(1H)-pyridinones and preparation, useful as cardiotonics
WO1993007137A1 (en) * 1991-10-11 1993-04-15 Smithkline Beecham Plc Pyridinol derivatives as medicaments
WO2003063874A1 (en) * 2002-01-29 2003-08-07 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0677519A4 (en) * 1993-11-10 1996-04-03 Japan Tobacco Inc CHROMAN DERIVATIVE AND THERAPEUTIC USE THEREOF.
ES2306671T3 (es) * 1999-10-07 2008-11-16 Amgen Inc. Inhibidores de triazina quinasa.
CA2456985A1 (en) * 2001-08-15 2003-02-27 Icos Corporation 2h-phthalazin-1-ones and methods for use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0109628A1 (en) * 1982-11-18 1984-05-30 Sterling Drug Inc. 2(1H)-pyridinones and preparation, useful as cardiotonics
WO1993007137A1 (en) * 1991-10-11 1993-04-15 Smithkline Beecham Plc Pyridinol derivatives as medicaments
WO2003063874A1 (en) * 2002-01-29 2003-08-07 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds

Also Published As

Publication number Publication date
US7863280B2 (en) 2011-01-04
AU2005297570C1 (en) 2012-06-07
BRPI0516516A (pt) 2008-09-16
KR20070063005A (ko) 2007-06-18
EP1802578B1 (de) 2008-04-23
EP1802578A1 (de) 2007-07-04
WO2006042638A1 (de) 2006-04-27
DE102004050196A1 (de) 2006-04-20
CA2583565A1 (en) 2006-04-27
US20070281948A1 (en) 2007-12-06
MX2007003360A (es) 2007-05-23
PT1802578E (pt) 2008-07-07
DK1802578T3 (da) 2008-08-11
AU2005297570B2 (en) 2011-06-16
JP4875623B2 (ja) 2012-02-15
IL182093A0 (en) 2007-07-24
ES2304721T3 (es) 2008-10-16
AU2005297570A1 (en) 2006-04-27
JP2008516902A (ja) 2008-05-22
HK1107088A1 (en) 2008-03-28
ATE393146T1 (de) 2008-05-15
IL182093A (en) 2011-02-28
DE502005003866D1 (de) 2008-06-05
CN101035761A (zh) 2007-09-12

Similar Documents

Publication Publication Date Title
CN101035761B (zh) 作为聚(adp-核糖)聚合酶(parp)抑制剂、治疗由坏死或细胞程序死亡导致的组织损伤或疾病的3,6-取代的5-芳基氨基-1h-吡啶-2-酮衍生物和相关化合物
CN1968929B (zh) 取代的四氢-2h-异喹啉-1-酮衍生物、其制备方法以及其作为药物的用途
KR100908176B1 (ko) 인자 Ｘａ 억제제로서의 락탐-함유 화합물 및 그의 유도체
AU2002341693A1 (en) Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
JP2009023986A (ja) 抗癌剤としてのビアリール誘導体
NO313517B1 (no) 6-Fenylpyridyl-2-aminderivater, anvendelse av disse og farmasöytiske preparater inneholdende dem
JP2005511602A (ja) アントラニル酸アミドおよびｖｅｇｆ受容体チロシンキナーゼ阻害剤としてのその使用
JP2016539993A (ja) Ｎ−置換ピラゾリルグアニジンｆ１ｆ０−ａｔｐアーゼ阻害剤及びその治療用途
CN100427483C (zh) 邻氨基苯甲酰胺衍生物和其药学用途
HK1107088B (en) 3,6-substituted 5-arylamino-1h-pyidine-2-one derivatives and related compounds as poly(adp-ribose)polymerase (parp) inhibitors in the treatment of tissue damage or disease caused by necrosis or apoptosis
HK1100409B (en) Substituted tetrahydro-2h-isoquinolin-1-one derivatives, method for the production thereof, and use of the same as medicaments
KR101480759B1 (ko) 아자인돌 유도체 화합물, 이를 포함하는 Ｔｒｋ 저해제 조성물 및 Ｔｒｋ와 관련된 질환의 예방 및 치료용 약학 조성물

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1107088

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1107088

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100602

Termination date: 20131005